Drugs / rebimastat
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00024024 | Aug 2001 → Aug 2003 | sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00040755 | May 2002 → Jul 2006 | hormone-resistant prostate carcinoma, metastatic carcinoma in the bone, prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00039104 | Apr 2002 → Jan 2005 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00036621 | ? → Sep 2002 | breast cancer | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00006229 | Apr 2000 → Dec 2003 | lung cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rebimastat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00024024 ↗ |
| Known as | BMS 275291-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL76222 ↗ |
| Known as | BMS-275291 | “Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium.” PMID 18224669 ↗ Mar 2008 |
| Known as | D-2163 | ChEMBL registry synonym — accepted as the source's own label CHEMBL76222 ↗ |
| Action | Inhibit | “a novel, orally bioavailable MMP inhibitor” PMID 18224669 ↗ Mar 20086“Matrix metalloproteinase 14 inhibitor” CHEMBL76222 ↗ “Matrix metalloproteinase 13 inhibitor” CHEMBL76222 ↗ “Matrix metalloproteinase 8 inhibitor” CHEMBL76222 ↗ “Matrix metalloproteinase-2 inhibitor” CHEMBL76222 ↗ “Matrix metalloproteinase-1 inhibitor” CHEMBL76222 ↗ “Matrix metalloproteinase 9 inhibitor” CHEMBL76222 ↗ |
| Modality | Small molecule | — CHEMBL76222 ↗ |
| Route | Oral | “Patients receive oral BMS-275291 1-2 times daily.” NCT00024024 ↗ |
| Target | MMP1 | “Matrix metalloproteinase-1 inhibitor” CHEMBL76222 ↗ |
| Target | MMP13 | “Matrix metalloproteinase 13 inhibitor” CHEMBL76222 ↗ |
| Target | MMP14 | “Matrix metalloproteinase 14 inhibitor” CHEMBL76222 ↗ |
| Target | MMP2 | “Matrix metalloproteinase-2 inhibitor” CHEMBL76222 ↗ |
| Target | MMP8 | “Matrix metalloproteinase 8 inhibitor” CHEMBL76222 ↗ |
| Target | MMP9 | “Matrix metalloproteinase 9 inhibitor” CHEMBL76222 ↗ |